The evidence gathered indicates that SGLT2 inhibitors are effective in managing heart failure and improving the long-term survival of patients by enhancing cardiovascular outcomes, reducing hospitalization rates, and promoting overall quality of life. The gene discussed is SLC5A2; the disease is heart failure.